4-(4-METHOXYPHENYL)-1-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYLAZO)-6-(PYRROLIDIN-1-YL)-PYRIDIN-2(1H)-ONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AUXYQTGCESCUSN-QNEJGDQOSA-N
Smiles	COc1ccc(cc1)C2=CC(=O)N(C(=C2N=Nc3ccc(Cl)cc3)N4CCCC4)c5cccc(Cl)c5
InChI	InChI=1S/C28H24Cl2N4O2/c1-36-24-13-7-19(8-14-24)25-18-26(35)34(23-6-4-5-21(30)17-23)28(33-15-2-3-16-33)27(25)32-31-22-11-9-20(29)10-12-22/h4-14,17-18H,2-3,15-16H2,1H3/b32-31+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C28H24Cl2N4O2
Molecular Weight	519.42
AlogP	7.53
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	57.5
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	36.0

Assay Description	Organism	Bioactivity
Antimicrobial activity against Aspergillus clavatus MTCC 1323	Aspergillus clavatus	500.0 ug.mL-1
Antimicrobial activity against Aspergillus niger MTCC 282	Aspergillus niger	500.0 ug.mL-1
Antimicrobial activity against Candida albicans MTCC 227	Candida albicans	100.0 ug.mL-1
Antimicrobial activity against Streptococcus pyogenes MTCC 443 by broth microdilution method	Streptococcus pyogenes	500.0 ug.mL-1
Antimicrobial activity against Staphylococcus aureus MTCC 96 by broth microdilution method	Staphylococcus aureus	500.0 ug.mL-1
Antimicrobial activity against Pseudomonas aeruginosa MTCC 2488 by broth microdilution method	Pseudomonas aeruginosa	500.0 ug.mL-1
Antimicrobial activity against Escherichia coli MTCC 442 by broth microdilution method	Escherichia coli	100.0 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2235921

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).